ASHP CLINICAL SKILLS COMPETITION

PHARMACIST'S PATIENT DATA BASE FORM

Demographic and Administrative Information		
Name DG	Patient ID 54321	Room No.
Address Anytown, USA	wn, USA MD Smith	
	Pharmacy	
Date of Birth 8-16-50	Race Caucasian	Gender Male
Height 5'11'' Weight 180 1bs	Religion Catholic	
Admission Date	Occupation Mechanical	Engineer

History of Present Illness DC is a 48 yr old white male who is a new patient to your clinic
male who is a new patient to your clinic
after moving here from out of state. Had
received all previous medical care from his
primary clinc for 10 yrs before moving out
of the area. Here today requesting medi-
cation refills, has appt. with new primary
physician in 2 weeks.
physician in 2 weeks.
Past Medical History/Surgery
Hypertension X 5 years
Hyperlipidemia X l year (had 6 month trial
offdrug therapy before starting drug
therapy)
Family and Social History married, has 2 teenage
children. Tobacco: l pack per day
cigarettes for 25 years, quit 5 years ago,
restarted 3 months ago after moving, has
tried to quit but can't get through craving
Alcohol: 1-2 beers q 3-4 days
Lifestyle Exercise: no formal exercise, walks
the dog occasionally. Diet: follows no
particular diet, eats red meat 2-3 times/
week, does not eat the skins of meat, cuts
off excess fat, fried foods less than once/
week. No sweets. + salt to food.
Acute and Chronic Medical Problems
1
2.
3.
4.
5.
6.
7.
8.
O 1993, American Society of Hospital Pharmacists", Inc. All rights reserved.

Vital Signs	/Laborator	/ Data—Inil	ial/Followup
Date	10/10/		
Wt	180 lb		
Temp	98.6		
BP	152/96	· · · · · · · · · · · · · · · · · · ·	
Pulse	90		
. 0.00	-		
Tod	ay:		
Na 142			
K 4.4			
CI 100			
CO ₂ 28	,		
BUN 21	·		
Cr 1.1			
Glu 110			
Glyc Hgb	5.2%		
Ca			•
Phos			
T Prot			
Alb			
Hgb			
Hct			
WBC			
PLT			
AST 21	U/1		
ALT 2	U/1		
LDH 65			
	45 U/1		
Bili to	tal: 0.	2 mg/dl	
l yr a	go: 6	mo. ago:	Today:
T. Cho		255	270
Trig	130	130	130
LDL	192	190	200
HDL	42	40	42
		throug	nout
	erum Conc	entrations	
, Date			
Digoxir	<u> </u>		
Theo	·		
Gent/	00		
Vanco	oio		
Phenyl	oin		
		······································	

(continued)

ASHP CLINICAL SKILLS COMPETITION PHARMACIST'S PATIENT DATA BASE FORM

Current Drug Therapy			
Drug Name/Dose/Strength/Route	Prescribed Schedule	Duration Start-Stop Dates	Compliance/Dosing Issue
1. Metoprolol 50mg PO	BID	X 3 years	
2. E.C. Aspirin 325 mg PO	Q AM	X 6 months	
3. Lopid 600 mg PO	BID	X 6 months	
4. MVI PO	Q AM	X 5 years	
5. HCTZ 25 mg PO	Q AM	D/c 3 yr ago	failure to control
6. NO other BP or lipid m	edications in	the past	
7.			
8.			
9.			
10.			

Medications PTA		
1. N/A	6.	
2.	7.	
3.	8.	
4.	9.	
5.	10.	

Time Line: Circle actual administration times, and record appropriate medications and meals below. 8 9 10 11 12 1 2 3 4 5 6 8 9 10 11 12 1 2 3 4 5 midnight Metoprolol Metoprolol

Lopid Aspirin -MVI

Lopid

Allergies/Intolera		Alcoho	1-/ 03-4 084	Cost of Meds/month \$
Allergen	Reaction	Caffei Tobac	ne 3-4 cups/day	Insurance: PYes No Copay\$12/brand, \$6/ger
		hx.	SEE SUCIAL	Medicaid Annual Income
				\$ 53,000/yr

Notes Takes meds regularly, no problems paying for them. Family History: Father had an acute myocardial infarction at age 50, still alive. Mother has history of hypothyroidism for which she is controlled with meds.

O 1993, American Society of Hospital Pharmacists, Inc. All rights reserved.

(continued)

ASHP CLINICAL SKILLS COMPETITION PHARMACIST'S PATIENT DATA BASE FORM CONTINUED

Physical Exam: 51 year old, well-developed, slightly overweight male in no acute distress

Ht: 5'11" Wt: 180 lb BP 152/96

HR: 90 (took BP meds today)

HEENT: PERRLA conjunctiva WNL. No corneal arcus or xanthelasma

Skin: WNL

Cardiac: + S1, S2, -S3, -S4; no murmurs

Lungs: + breath sounds with good air movement

ABD: + BS, -splenomegaly, - masses

Neuro: A & O X 3, CN I-XII intact, motor 5/5. DTR symmetrical and WNL

Upon questioning: patient reports no problems with CP, SOB, dizziness, fatigue, edema, paresthesias. He knows he needs to stop smoking but is not concerned about other lifestyle modifications. "I'm healthy, I feel fine."

Lab:

From previous medical records transferred here:

1 year ago: Chol: 260 Trig: 130 LDL: 192 HDL: 42

Step I diet initiated, exercise encouraged

6 months ago: Chol: 255 Trig: 130 LDL: 190 HDL: 40

BP 132/84 LFTs WNL

Step II diet initiated, exercise encouraged, Lopid 600 mg BID started

Today's Labs: Na 142 Cl 100 BUN 21 FBG 110 10/10/98 K 4.4 CO2 28 Cr 1.1 Hgb A1c 5.2%

LFTs all WNL

Total Chol 270 Trig: 130 LDL: 200 HDL: 42

ASHP CLINICAL SKILLS COMPETITION Drug Therapy Assessment Worksheet Answer Key

1. Correlation between Drug Therapy and Medical Problems

Hypertension: Metoprolol Hypercholesterolemia: Lopid CAD prevention: EC ASA

2. Appropriate drug selection:

A problem exists: The patient's cholesterol problem is not controlled on the current regimen of Lopid. Lopid should be reserved for problems of hypertriglyceridemia, not for reduction of LDL. The patient's goal LDL is <130 considering risk factors of: male > 45 years of age, hypertension, current smoker, family history of AMI in male relative <55 years of age. (Following NCEP-II recommendations). Therefore he has a 35% LDL reduction necessary. Suggest stopping Lopid and change to the following: an appropriate starting dose would be any of the statins as follows:

Lipitor 10 mg QD

Baycol 0.3 mg QHS (will probably not be strong enough to reach LDL goal) Lescol 20 mg QHS (will need to increase to 80 mg qhs to achieve adequate reduction in LDL)

Mevacor 20 mg QHS (may need to increase to 80 mg qhs)
Pravachol 20 mg QHS (will need to increase to 40 mg qhs)
Zocor 10 mg QHS (may need to increase to 20 mg qhs)

The most cost-effective medication for the necessary LDL reduction is Lipitor 10 mg qhs.

Monitoring recommended:

Lipitor: Baseline LFTs, 12 weeks after initiation or dose change, then semiannually. Check Lipid profile in 2-4 weeks.

Pravachol: Baseline LFTs, 12 weeks after initiation or dose change. Check lipid profile in 4-6 weeks.

Mevacor: Baseline LFTs, 6 & 12 weeks after initiation or dosage change, semiannually. Check lipid profile in 4-6 weeks.

Lescol: Baseline LFTs, 6 & 12 weeks after initiation or dosage change, semiannually. Check

lipid profile in 4-6 weeks. Baycol: Baseline LFTs, 6 & 12 weeks after initiation or dosage change, semiannually. Check lipid profile in 4-6 weeks.

Zocor: Baseline LFTS, 6 and 12 months after initiation or dose change. Check lipid profile in 4-6 weeks.

CPKs only monitored if patient is symptomatic of muscle aches, weakness.

Or as an alternative: start with Niaspan starter packet or cholestyramine powder, but need to monitor closely due to potential compliance problems with each. Published research does not suggest that either drug alone will reduce the LDL the necessary 35%, so both of these choices would be considered secondary to starting with a statin.

3. Drug Regimen:

A problem exists. The patient's blood pressure is not adequately controlled, despite compliance with current metoprolol regimen. Suggest increasing dose to 100 mg BID

- 4. Therapeutic Duplication: No problem exists
- 5. Drug Allergy or intolerance: No problem exists
- 6. Adverse Drug Events No problem exists
- 7. Drug Interactions: No problem exists
- 8. Social or recreational drug use Patient should be encouraged to drink decaffeinated beverages due to potential for caffeine to increase BP Patient should be encouraged to decrease sodium intake Patient should be encouraged to stop smoking and may recommend nicotine patches or Zyban to help decrease cravings
- 9. Failure to receive drug therapy: No problem exists
- 10. Financial impact: No problem exists
- 11. Patient Knowledge of Drug Therapy No problem exists

Shaded area is evaluated for Competition

ASHP CLINICAL SKILLS COMPETITION

PHARMACIST'S CARE PLAN

Patient DG	
	Observation
Location/Room	Pharmacist
Location/ Room	
	Date

Health Care Needed	Pharmacotherapeutic Goal	Recommendations for Therapy	Monitoring	Desired	Monitoring
Mgmt of HTN to	Control of RP	Increase			Frequency
prevent morbidity	without ADRs	Metoprolol to 100 mg BID	· ·		BP in 2 wk at MD appt Compliance at every
Mgmt of Cholesterol to prevent morbidity	Control of cholesterol w/ diet & meds	D/C Lopid Start statin at appropriate doses Diet, exercise	Lipids, LFTs, symptoms, compliance	LDL less than 130	visit LFTs depen on therapy chosen(see DTAW). Compliance & ADRs q visit
Stop smoking	Stop smoking	patches. Encourage smoking	ADRs from	NO SMOKING	Each visit
Improve diet & exercise	,	Decrease caffeine & salt intake. Exercise 30 min. 3-4 times/week. Follow Step II	frequency		Each visit
Risk for AMI/ Stroke	No events	Discuss life- style mod. such as smoking/ exercise/diet/	1.	·	Reinforce each visit
		cholesterol to reduce risk of future AMI or stroke			

	Mgmt of HTN to prevent morbidity Mgmt of Cholesterol to prevent morbidity Stop smoking Improve diet & exercise	Mgmt of HTN to prevent morbidity Mgmt of Control of BP without ADRs Mgmt of Cholesterol to prevent morbidity Stop smoking Stop smoking Stop smoking Improve diet & exercise Risk for AMI/ No events	Mgmt of HTN to prevent morbidity Mgmt of Control of BP without ADRs Mgmt of Cholesterol to prevent morbidity Stop smoking Assess need for Zyban or nicoting patches. Encourage smoking cessation. Decrease caffeing & salt intake. Exercise 30 min. 3-4 times/week. Follow Step II Diet. Discuss life—style mod. such as smoking/exercise/diet/alcohol reduction as well as BP & cholesterol to reduce.risk of future AMI or	Mgmt of HTN to prevent morbidity Mgmt of Control of BP without ADRs Mgmt of Cholesterol to prevent morbidity Mgmt of Cholesterol working Start statin at appropriate doses Diet, exercise Stop smoking Stop smoking Assess need for Zyban or nicoting patches. Improve diet & exercise Improve diet & exercise Risk for AMI/ Stroke Risk for AMI/ Stroke Mgmt of Control of Cholesterol working D/C Lopid Start statin at appropriate doses Diet, exercise Assess need for Zyban or nicoting patches. Encourage smoking ADRs from drug tx cessation. Decrease caffeine & Weight, frequency of each No events No events No events Risk for AMI/ Stroke	Mgmt of HTN to prevent without ADRs without ADRs Mgmt of Control of BP without ADRs Mgmt of Control of Cholesterol to prevent morbidity Mgmt of Control of Cholesterol w/ diet & meds Stop smoking Assess need for Zyban or nicoting symptoms, compliance Than 130 SMOKING ADRs from drug tx cessation. Decrease caffeine & Sanoking drug tx frequency of each Stop smoking Stop smoking Stop smoking Stop smoking Assess need for Zyban or nicoting symptoms, compliance Encourage smoking Encourage smoking SMOKING ADRS from drug tx Stop smoking Stop smoking Stop smoking Stop smoking Stop smoking Assess need for SMOKING ADRS from drug tx Stop smoking Encloped Stop smoking Stop smoking